Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech Platform

NEW YORK and SALT LAKE CITY, March 31, 2026 (GLOBE NEWSWIRE) -- Citeline, a leader in clinical solutions for the life sciences industry, today announced an expanded strategic partnership with ...
Zacks Investment Research on MSN

Recursion Pharmaceuticals (RXRX) down 16.5% since last earnings report: Can it rebound?

A month has gone by since the last earnings report for Recursion Pharmaceuticals (RXRX). Shares have lost about 16.5% in that time frame, underperforming the S&P 500. Will the recent negative trend ...
Stocktwits on MSN

Nvidia’s expanding role in AI-driven drug discovery, clinical research could fuel growth, says Goldman Sachs

Goldman Sachs says rising demand for advanced computing power in specialized industries continues to strengthen Nvidia’s ...

Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer

Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Vicki Goodman, M.D., will become Recursion’s Chief Medical Officer ...

2 AI Healthcare Stocks to Buy Right Now

While the advent of artificial intelligence (AI) has obviously changed the world, not every utilization of AI has necessarily ...

Recursion Pharmaceuticals Details AI-Driven Drug Pipeline, Sanofi/Roche Milestones, Runway to 2028

Chief Financial Officer Ben Taylor outlined the company’s integrated approach to AI-enabled drug discovery and development, ...
FierceBiotech

JPM24: Nvidia expands drug discovery footprint with new Amgen, Recursion alliances

Nvidia’s forthright ambitions to expand its drug development footprint are coming into focus, with the global computing powerhouse announcing a trio of new initiatives including a new collaboration ...
Zacks.com on MSN

Recursion Pharmaceuticals (RXRX) Advances While Market Declines: Some Information for Investors

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.37, moving +1.51% from the previous trading session. This move outpaced the S&P 500's daily loss of 0.28%. Elsewhere, the Dow ...
The Motley Fool

The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why.

Recursion Pharmaceuticals is merging with Exscientia. The new entity will have the backing of quite a few big names in pharma. It'll also have an even more capable drug discovery and development ...
STAT

Recursion CEO: Biotech’s rainy season is not over — but we must race ahead

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...
Forbes

What's Happening With RXRX Stock?

Recursion Pharmaceuticals (NASDAQ:RXRX) has experienced notable share price fluctuations in 2025, falling 27% year-to-date and trading over 55% beneath its 52-week high of $12. In spite of this ...
TheServerSide

Recursion vs Iteration: What's the difference?

Community driven content discussing all aspects of software development from DevOps to design patterns. The factorial of 5 is 120. The factorial of 10 is 3,628,800. Programmers can take one of two ...